The Cancer Genetics and Genomics Laboratory is offering a new test that interrogates the myeloid differentiation primary response 88 (MYD88) gene to detect the L265P mutation. MYD88 L265P is identified in approximately 90% of confirmed lymphoplasmacytic lymphoma (LPL) cases and therefore increases the likelihood for a MYD88 related LPL diagnosis. Additional details of the test can be found in the memo below.